Vedanta Biosciences retweeted
Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy - endpoints.news/vedanta-gets-β¦
Vedanta Biosciences retweeted
Today we announced @VedantaBio secured additional financing, led by AMR Action Fund and BNP Paribas Asset Management Alts, and additional funding from BARDA, to support the RESTORATiVE303 Phase 3 study of VE303 for recurrent C. difficile infection
businesswire.com/news/home/2β¦
Vedanta Biosciences retweeted
Thank you to @CARB_X developers, partners, and investors who gathered in Vienna, Austria on April 10 for CARB-X's annual Investor Day! More than 20 developers in advanced product stages presented to downstream investors interested in supporting antimicrobial products.
Vedanta Biosciences retweeted
If you have mild to moderate #ulcerativecolitis, and have not taken biologic medications or Janus Kinase (JAK) inhibitors, the VE202 study may be right for you. Learn more: bit.ly/3ZZ0FqD #sponsored #ulcerativecolitis #VE202 #UC
Vedanta Biosciences retweeted
The Vedanta team is very excited to share our latest findings coming out of our successful VE303 Ph2 study in CDI. #IDWeek2024
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
businesswire.com/news/home/2β¦
Vedanta Biosciences retweeted
This analysis show the positive impact of VE303 treatment on the levels of antibiotic resistance genes in the gut microbiomes of patients enrolled in the Ph2 CONSORTIUM study, revealing associations between higher dosage and colonization of VE303 strains with lower levels of ARGs
Vedanta Biosciences retweeted
@themissingmenon will be giving the late-breaking oral presentation this Friday in LA as part of Infectious Diseases Week (IDWeek) 2024
Vedanta Biosciences retweeted
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
businesswire.com/news/home/2β¦
Vedanta Biosciences retweeted
We are recruiting a Bioinformatician to join our Systems Biology team at Vedanta. Come work with us to advance defined bacterial consortia as a new drug modality!
job-boards.greenhouse.io/vedβ¦
Vedanta Biosciences retweeted
I am looking to hire a Bioinformatics Scientist to join the Systems Biology team @VedantaBio. Considering candidates in Boston area and up to 100% remote, if in US. Apply today! Please share! job-boards.greenhouse.io/vedβ¦
Vedanta Biosciences retweeted
πππ₯π€π’π§π πππ’ππ§ππ: @VedantaBio's founder and CEO @bernatolle shares an expert take on microbiome drug development.
Full video: biotechtv.com/post/vedanta-bβ¦
Vedanta Biosciences retweeted
We are excited to announce the publication of our new article today:
nature.com/articles/s41586-0β¦
Vedanta Biosciences retweeted
Exciting collab with @Honda1Kenyaβs lab, out today in @Nature: A set of microbial strains taken from a human faecal donor can decolonize multidrug-resistant Enterobacteriaceae in the gut, including species associated with #IBD. (1/3) nature.com/articles/s41586-0β¦
Vedanta Biosciences retweeted
We did not have a blueprint for how to get an LBP ready for a registrational study. In the last couple of years, the process development, analytical development, manufacturing, and quality teams @vedantabio worked tirelessly navigating uncharted waters /7
Vedanta Biosciences retweeted
The Phase 3 study, RESTORATiVE303, is now underway in the US. We plan to expand enrollment to include >20 countries. It is a registrational study designed to support a BLA submission
/6
